Zynex, Inc.

Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Zynex, Inc. |
Ticker: | Ticker: ZYXI |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ:ZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On March 11, 2025, after market hours, Zynex released its fourth quarter and full year 2024 financial results, revealing a revenue “shortfall” in the quarter “due to slower than normal payments from certain payers.” The Company further revealed it has been “notified that Tricare has temporarily suspended payments as they review prior claims.” Tricare is the healthcare program for uniformed service members and “currently represents approximately 20-25% of [the Company’s] annual revenue.” On this news, the price of Zynex shares declined by $3.59 per share, or approximately 51%, from $7.00 per share on March 11, 2025, to close at $3.41 on March 12, 2025.
On March 11, 2025, after market hours, Zynex released its fourth quarter and full year 2024 financial results, revealing a revenue “shortfall” in the quarter “due to slower than normal payments from certain payers.” The Company further revealed it has been “notified that Tricare has temporarily suspended payments as they review prior claims.” Tricare is the healthcare program for uniformed service members and “currently represents approximately 20-25% of [the Company’s] annual revenue.” On this news, the price of Zynex shares declined by $3.59 per share, or approximately 51%, from $7.00 per share on March 11, 2025, to close at $3.41 on March 12, 2025.